(Q42855117)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author

Stamatis-Nick Liossis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Dimitrios Daoussis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Georgios Yiannopoulos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Andrew P Andonopoulos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

3 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

International journal of rheumatology

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

214013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

9 February 2020

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Cyclophosphamide versus placebo in scleroderma lung disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B lymphocytes and systemic sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Systemic and cell type-specific gene expression patterns in scleroderma skin

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Rituximab in the treatment of antisynthetase syndrome

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3150146

Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab

16 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2011%2F214013

B cell infiltration in systemic sclerosis-associated interstitial lung disease

21 January 2018

1 reference

12 December 2020

BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice

1 reference

12 December 2020

Quantitative genetic variation in CD19 expression correlates with autoimmunity

1 reference

12 December 2020

CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model

1 reference

12 December 2020

Structural features of interstitial lung disease in systemic sclerosis

1 reference

12 December 2020

Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes

1 reference

12 December 2020

Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis

1 reference

12 December 2020

Is rituximab a potential new therapy in systemic sclerosis? new evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin

1 reference

12 December 2020

Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/214013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826145%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference